Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New serum fights age spots in 16-Week trial

NCT ID NCT07468175

Symptom relief Sponsor: Revision Skincare Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a dark spot corrector serum along with two different skincare routines in 48 women with moderate age spots. Over 16 weeks, doctors checked if the spots got lighter, smaller, or less noticeable. The goal was to see if the treatment was safe and effective for improving skin tone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

48 people

The number who actually took part.

Started

Oct 2024

Finished

Mar 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 65 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 2\. In good general health (physical, mental, and social well-being, not merely the absence of disease/infirmity), according to subject self-report. 3\. Having Fitzpatrick skin type I-IV (refer to Appendix I: Fitzpatrick Skin Type). 4\. Having moderate (score of 4-6 according to a modified Griffiths scale,1 where 0=none and 9=severe) discrete hyperpigmentation (solar lentigines \[age spots/sun spots\]) on the global face. 5\. Having at least 1 dark spot (solar lentigo \[age spot or sun spot\]) with moderate intensity (score 4-6) on each side of the face (with no more 0.5 point difference between scores on each side of the face) that is at least 3 mm in size and clearly discernible by the clinical grader and visible in all images at baseline to be tracked as target spots during the study. 6\. Self-perceived very bothersome hyperpigmentation (darkening), including spots, on the global face. Exclusion Criteria: 1. Having been diagnosed with known allergies to skin care products. 2. Having a known reactivity to niacinamide, sunflower seed, coconut, rosemary, barley, goji, sandalwood, licorice root, radish root, beeswax, and/or yeast. 3. Breastfeeding, pregnant, or planning to become pregnant during the study according to subject self-report. 4. Having a history of skin cancer within the past 5 years. 5. Currently using oral or topical prescription medications for acne such as doxycycline, minocycline, clindamycin, Bactrim, tetracycline, erythromycin, azelaic acid, benzoyl peroxide, Dapsone, or sodium sulfacetamide.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dark spots are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hyperpigmentation hyperpigmentation of the skin lentigo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dark spots Hyperpigmentation

Contacts and locations

Locations

  • SGS Dallas Research Center

    Richardson, Texas, 75081, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.